Bli medlem
Bli medlem

Du är här


Inhalation Sciences: Inhalation Research Services signs CRO contract worth 898 000 SEK with ISR Immune System Regulation AB for part of toxicology program on new inhaled COVID-19 vaccine

(Stockholm June 18, 2021) Inhalation Research Services (IRS), the contract research organization of Inhalation Sciences AB, has signed a contract with Stockholm-based research company ISR Immune System Regulation AB worth 898 000 SEK. The contract is for part of the toxicology program of a novel inhaled vaccine against SARS-CoV-2, the virus that causes COIVD-19.

ISR Immune System Regulation AB is an innovation-focused preclinical and clinical research company based in Sweden developing novel drugs with a focus on immunotherapy. The contract research order is for the initial part of the toxicology program characterizing the aerosols of a novel inhaled Covid-19 vaccine. The results will be used as a basis for the inhalation procedure in the in vivo exposures.

IRS' aerosol characterization capabilities deliver precise, predictive voluminous data that could then be used to establish the settings for the next stage of the toxicology program, potentially reducing risk and accelerating the program between preclinical and clinical research stages.

ISAB CEO Manoush Masarrat: "This is a huge milestone and yet another recognition of the quality of our technology.  As an inhalation company we have clearly been in discussions around Covid-19 research during the recent months and we are proud now to get the chance to be part of providing new solutions for such a global challenge. Our ability to offer a range of exposure modules, all connected to PreciseInhale, can really reduce risk and translational errors between research stages, increasing safety and ultimately accelerating research and drug development. We're looking forward to start work."

For more information on Inhalation Sciences, please contact:

Manoush Masarrat, CEO


Mobile: +46 (0)73 628 9153

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.